Clinical trial
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
NCT02624570 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Expanded access
- Overall status
- No longer available
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- Not reported
- Sites
- 44
Conditions
As the registry lists them; a condition with its own page is linked.
acute myeloid leukemia (aml) with, flt3 mutation, internal tandem duplication (itd) or tyrosine kinase domain (tkd)